Coronary Arteriosclerosis

Cardiovascular
7
Pipeline Programs
9
Companies
11
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
4
Early DiscoveryClinical DevelopmentMarket

On Market (3)

Approved therapies currently available

U
PRASUGRELApproved
prasugrel
Unknown Company
oral2018
U
PRASUGREL HYDROCHLORIDEApproved
prasugrel
Unknown Company
oral2023
U
ROSUVASTATIN CALCIUMApproved
rosuvastatin calcium
Unknown Company
oral2016

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
modified-release dipyridamole/aspirinPhase 41 trial
Active Trials
NCT00129038Completed11
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
PrasugrelPhase 3
DS
Daiichi SankyoChina - Shanghai
1 program
1
PrasugrelPhase 31 trial
Active Trials
NCT00097591Completed13,619Est. Jul 2007
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Rosuvastatin calciumPhase 31 trial
Active Trials
NCT00240318Completed450Est. Nov 2005
OrbusNeich
OrbusNeichChina - Hong Kong
4 programs
OrbusNeich Combo stent™N/A1 trial
OrbusNeich Combo stent™N/A1 trial
OrbusNeich Scoreflex TRION/A1 trial
Support C Post-Market RegistryN/A1 trial
Active Trials
NCT02073565Completed572Est. Dec 2021
NCT02542007Completed440Est. Jun 2021
NCT05929313Completed210Est. May 2024
+1 more trials
Providence Therapeutics
1 program
Comparison of Cardiac Computed Tomography for the Detection of Coronary Artery Disease With Nuclear N/A1 trial
Active Trials
NCT00352937CompletedEst. Dec 2009
Bristol Myers Squibb
1 program
Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)N/A1 trial
Active Trials
NCT00213746Completed75Est. Dec 2005
Acarix
AcarixSweden - Malmö
1 program
Risk Stratification for Coronary Artery Disease With Type 2 Diabetic PatientsN/A1 trial
Active Trials
NCT02494557CompletedEst. Mar 2015
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
Stents, Drug Eluting Stents, and CABG- Financial and Clinical Impact.N/A1 trial
Active Trials
NCT00394680Completed700Est. May 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Boehringer Ingelheimmodified-release dipyridamole/aspirin
Daiichi SankyoPrasugrel
AstraZenecaRosuvastatin calcium
OrbusNeichSupport C Post-Market Registry
OrbusNeichOrbusNeich Scoreflex TRIO
OrbusNeichOrbusNeich Combo stent™
AcarixRisk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients
OrbusNeichOrbusNeich Combo stent™
Jerusalem PharmaceuticalsStents, Drug Eluting Stents, and CABG- Financial and Clinical Impact.
Providence TherapeuticsComparison of Cardiac Computed Tomography for the Detection of Coronary Artery Disease With Nuclear
Bristol Myers SquibbEvaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)

Clinical Trials (11)

Total enrollment: 16,359 patients across 11 trials

NCT00129038Boehringer Ingelheimmodified-release dipyridamole/aspirin

Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients

Start: Apr 200411 patients
Phase 4Completed
NCT00097591Daiichi SankyoPrasugrel

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

Start: Nov 2004Est. completion: Jul 200713,619 patients
Phase 3Completed
NCT00240318AstraZenecaRosuvastatin calcium

A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)

Start: Nov 2002Est. completion: Nov 2005450 patients
Phase 3Completed
NCT06678490OrbusNeichSupport C Post-Market Registry

Support C Post-Market Registry

Start: Jul 2025Est. completion: Feb 2029282 patients
N/AActive Not Recruiting
NCT05929313OrbusNeichOrbusNeich Scoreflex TRIO

Scoreflex TRIO - Scoring PTCA Catheter

Start: Apr 2023Est. completion: May 2024210 patients
N/ACompleted
NCT02542007OrbusNeichOrbusNeich Combo stent™

Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions

Start: May 2015Est. completion: Jun 2021440 patients
N/ACompleted
NCT02494557AcarixRisk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients

Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients

Start: Sep 2014Est. completion: Mar 2015
N/ACompleted
NCT02073565OrbusNeichOrbusNeich Combo stent™

HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

Start: Feb 2014Est. completion: Dec 2021572 patients
N/ACompleted
NCT00394680Jerusalem PharmaceuticalsStents, Drug Eluting Stents, and CABG- Financial and Clinical Impact.

Stents, Drug Eluting Stents, and CABG- Financial and Clinical Impact.

Start: Nov 2006Est. completion: May 2007700 patients
N/ACompleted
NCT00352937Providence TherapeuticsComparison of Cardiac Computed Tomography for the Detection of Coronary Artery Disease With Nuclear

Comparison of Cardiac Computed Tomography for the Detection of Coronary Artery Disease With Nuclear Stress Test

Start: Mar 2006Est. completion: Dec 2009
N/ACompleted
NCT00213746Bristol Myers SquibbEvaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)

Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)

Start: Oct 2003Est. completion: Dec 200575 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
22h ago
From $150K/yr

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
23h ago

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
23h ago

Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
23h ago
$100K - $135K/yr

Clinical Consultant

Johnson & Johnson
North Ryde, New South Wales, Australia
23h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
9 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)